Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $60.40 Consensus Target Price from Analysts

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has been given an average recommendation of “Moderate Buy” by the thirteen analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $60.40.

IMCR has been the topic of a number of research analyst reports. UBS Group set a $55.00 target price on shares of Immunocore and gave the company a “buy” rating in a research note on Wednesday, January 7th. Wall Street Zen raised Immunocore from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research note on Wednesday, October 22nd. Zacks Research upgraded Immunocore from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 7th. Finally, Morgan Stanley raised their target price on Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a report on Monday, November 10th.

Immunocore Stock Up 1.8%

Shares of IMCR stock opened at $33.35 on Thursday. The stock’s 50 day simple moving average is $36.06 and its 200 day simple moving average is $34.57. Immunocore has a twelve month low of $23.15 and a twelve month high of $40.71. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -58.51 and a beta of 0.78.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.32. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The company had revenue of $103.69 million for the quarter, compared to the consensus estimate of $137.29 million. During the same quarter last year, the company posted $0.17 earnings per share. The company’s revenue for the quarter was up 29.2% compared to the same quarter last year. As a group, research analysts predict that Immunocore will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Immunocore

Several large investors have recently bought and sold shares of IMCR. GAMMA Investing LLC increased its holdings in shares of Immunocore by 51.6% during the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company’s stock worth $33,000 after purchasing an additional 311 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Immunocore by 4,696.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock valued at $41,000 after buying an additional 1,268 shares during the period. Elevation Point Wealth Partners LLC acquired a new stake in Immunocore during the second quarter worth about $42,000. Osaic Holdings Inc. increased its stake in Immunocore by 117.4% during the second quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock valued at $97,000 after acquiring an additional 1,700 shares during the period. Finally, State of Tennessee Department of Treasury acquired a new position in Immunocore in the 2nd quarter valued at approximately $132,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.